Voyager Therapeutics, INC 10-Q quarterly reports

Voyager Therapeutics' Q2 2026 Form 10-Q details progress in neurological disease programs, including VY1706 and VY7523, alongside collaborations with Novartis and Neurocrine, while managing operational expenses and cash runway.

Voyager Therapeutics reports Q1 2026 results with reduced operating expenses and a strategic focus on key pipeline programs, while cash runway extends into 2028.

Voyager Therapeutics reported a significant increase in net loss and a sharp decline in collaboration revenue for Q3 2025, alongside a partial termination of key programs by Novartis.

Voyager Therapeutics reports a significant increase in net loss for Q2 2025, driven by strategic restructuring and R&D investments, while extending cash runway into 2028.

Voyager Therapeutics reports a net loss of $31.0 million for Q1 2025 while progressing its gene therapy and antibody programs targeting neurological diseases.

Voyager Therapeutics reported its Q3 2024 financial results, highlighting progress in its pipeline programs and strategic collaborations with Neurocrine and Novartis.

Voyager Therapeutics reported its second quarter 2024 financial results, highlighting progress in its clinical programs and strategic collaborations.

Voyager Therapeutics reported its first quarter 2024 financial results, highlighted by progress in its clinical programs and strategic collaborations.